SF 2645: Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision

Plain-language summary

SF 2645 is a bill introduced in the Minnesota Senate on March 17, 2025. According to its official title, it concerns: Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision. Primary sponsor: Liz Boldon (Democratic-Farmer-Labor). It lists 2 additional sponsors. Most recent recorded action (March 17, 2025): Referred to Health and Human Services.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written